Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

FST-201 (dexamethasone 0.1%) Otic Suspension

Phase 3 · small molecule · Acute Fungal Otitis Externa

FST-201 (dexamethasone 0.1%) Otic Suspension for Acute Fungal Otitis Externa is a Phase 3 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 3 small molecule terminated

Internal code FST201-AFOE-02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 3
Modality
small_molecule
Indication
Acute Fungal Otitis Externa
Status
terminated
Trials
1